ReviewiScience2026
Adaptive epithelial-mesenchymal bi-directional transition: A key invasive plasticity for tumor metastasis.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition (EMT) is a reversible cellular program that allows epithelium-derived cells to acquire mesenchymal phenotypes, whereas mesenchymal-epithelial transition (MET) enables mesenchymal cells to regain epithelial properties. The capacity for EMT and MET, known as epithelial-mesenchymal plasticity (EMP), represents an indispensable mechanism of invasive plasticity for tumor progression during the spatiotemporal invasion-metastasis cascade. In this review, we elucidate the pivotal role of EMP in tumor metastasis and treatment resistance, as well as the latest understanding of the molecular mechanisms that regulate this cellular characteristic. We further summarize the methodology and technology for evaluating EMP and discuss the clinical translational potential of targeting EMP-related signaling pathways as a personalized anti-metastasis therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.